367501-39-1

Basic information

• Product Name: Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate
• Synonyms: Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate
• CAS NO: 367501-39-1
• Molecular Formula: C₁₄H₁₈O₅
• Molecular Weight: 266.28972
• Mol File: 367501-39-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate(367501-39-1)
• EPA Substance Registry System: Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate(367501-39-1)

Safety Data

• Hazardous Substances Data: 367501-39-1(Hazardous Substances Data)

Usage

General Description

Methyl 3-(2-(tert-butoxy)-2-oxoethoxy)benzoate is a chemical compound that is commonly used as a fragrance ingredient, UV absorber, and preservative enhancer in various personal care and cosmetic products. It is an ester derivative of benzoic acid and is composed of a benzene ring with a carboxylic ester functional group attached to a chain containing an oxoethoxy and tert-butoxy group. This chemical compound is known for its ability to provide a pleasant and long-lasting scent, protect the skin from UV radiation, and enhance the shelf life of products by preventing bacterial and fungal growth. However, it is important to use this compound in controlled concentrations as excessive exposure can cause skin irritation and other adverse health effects.

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 99-06-9 3-Carboxyphenol 

Downstream Products

• 1072004-24-0 methyl 3-[2-({2-[(tert-butoxycarbonyl)(methyl)amino]-4-(2,3-dihydro-1-benzofuran-6-yloxy)phenyl}amino)-2-oxoethoxy]benzoate 
• 1072002-33-5 3-{[6-(2,3-dihydro-1-benzofuran-6-yloxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoic acid 
• 1072004-25-1 methyl 3-{[6-(2,3-dihydro-1-benzofuran-6-yloxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoate monohydrochloride 
• 113496-11-0 [3-(methoxycarbonyl)phenoxy]acetic acid 
• 313709-63-6 3-Carboxyphenoxyacetic acid tert-butyl ester 
• 500866-01-3 (3-carbamoyl-phenoxy)-acetic acid 
• 1878-61-1 3-carboxyphenoxyacetic acid 
• 1354718-43-6 N-((S)-6-amino-4,5,6,7-tetrahydro-benzothiazol-2-yl)-3-[(4-cyano-phenylcarbamoyl)-methoxy]-benzamide 
• 1354720-95-8 ((S)-2-{3-[(4-cyano-phenylcarbamoyl)-methoxy]-benzoylamino}-4,5,6,7-tetrahydro-benzothiazol-6-yl)-carbamic acid tert-butyl ester 
• 1053102-15-0 3-[(4-cyano-phenylcarbamoyl)-methoxy]-benzoic acid 
• 1354720-94-7 3-[(4-cyano-phenylcarbamoyl)-methoxy]-benzoic acid methyl ester 

Relevant articles and documents

Discovery of DS-6930, a potent selective PPARγ modulator. Part I: Lead identification

The lead identification of a novel potent selective PPARγ agonist, DS-6930 is reported. To avoid PPARγ-related adverse effects, a partial agonist was designed to prevent the direct interaction with helix 12 of PPARγ-LBD. Because the TZD group is known to

RHO KINASE INHIBITORS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase-mediated disorders selected from hypertension, atherosclerosis, restenosis, stroke, myocardial infarction, heart failure, coronary artery disease, peripheral artery disease, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, erectile dysfunction, renal disease, organ failure, asthma, glaucoma, cancer, Alzheimer's disease, multiple sclerosis, spinal cord injury, neuropathic pain, rheumatoid arthritis, psoriasis inflammatory bowel disease, and combinations of such disorders.

FUSED BICYCLIC HETEROARYL DERIVATIVES

Problem to be Solved The present invention relates to a novel fused bicyclic heteroaryl derivative or a pharmacologically acceptable salt thereof, which has an excellent hypoglycemic effect or treats and/or prevents the onset of a disorder of carbohydrate